Data in Brief (Jun 2022)

Data on immunogenicity and reactogenicity to COVID-19 vaccination among patients receiving maintenance dialysis

  • Hristos Karakizlis,
  • Christian Nahrgang,
  • Kevin Strecker,
  • Jiangping Chen,
  • Mostafa Aly,
  • Heiko Slanina,
  • Christian G. Schüttler,
  • Isla Esso,
  • Martin Wolter,
  • Darina Todorova,
  • Sönke Jessen,
  • Andrea Adamik,
  • Claudio Ronco,
  • Werner Seeger,
  • Rolf Weimer,
  • Martina Sester,
  • Horst-Walter Birk,
  • Faeq Husain-Syed

Journal volume & issue
Vol. 42
p. 108271

Abstract

Read online

Compared with the general population, patients receiving maintenance dialysis are at increased risk for morbidity and mortality associated with coronavirus disease 2019 (COVID-19). Currently, data on severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-specific immunity post-vaccination in patients on maintenance dialysis are scarce given that the effectiveness of the vaccines has not been explicitly tested in this population due to their common exclusion from SARS-CoV-2 vaccination trials. We herein present data of the specific cellular (interferon-γ and interleukin-2 ELISpot assays) and humoral immune responses (dot plot array and chemiluminescent microparticle immunoassay) at 4 weeks and 6 weeks following a single dose or a complete homologous dual dose SARS-CoV-2 vaccine regimen in 60 adult patients on maintenance dialysis (six with a history of COVID-19). The data was produced in a framework of a project focused on a) quantifying the immune response after full vaccination, b) evaluating the short-term durability of immune response, and c) examining the reactogenicity of SARS-CoV-2 vaccine regimens in patients on maintenance dialysis.

Keywords